Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

DEXAMETHASONE Solution for injection (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Dexamethasone 3.8 mg/ml solution for injection.

Qualitative and quantitative composition

Each one ml contains 3.8 mg dexamethasone (as sodium phosphate) which is equivalent to 5.0 mg dexamethasone sodium phosphate. Excipient with known effect: Sodium: <1 mmol sodium (23 mg) per dose. For the ...

Pharmaceutical form

Solution for injection. Colourless aqueous solution.

Therapeutic indications

Corticosteroid. For use in certain endocrine and non-endocrine disorders responsive to corticosteroid therapy. Systemic (intravenous or intramuscular) administration Dexamethasone solution for injection ...

Posology and method of administration

DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. In neonates, especially the premature infant, only preservative-free ...

Contraindications

Systemic infection unless specific anti-infective therapy is employed. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Local injection of a glucocorticoid is ...

Special warnings and precautions for use

A Patient Information Leaflet should be supplied with this product. Severe allergic reactions Rare instances of anaphylactoid/anaphylactic reactions with a possibility of shock have occurred in patients ...

Interaction with other medicinal products and other forms of interaction

Rifampicin, rifabutin, ephedrine, carbamazepine, phenylbutazone, phenobarbital, phenytoin, primidone, and aminoglutethimide enhance the metabolism of corticosteroids and its therapeutic effects may be ...

Pregnancy and lactation

Pregnancy The ability of corticosteroids to cross the placenta varies between individual drugs, however, dexamethasone readily crosses the placenta. Administration of corticosteroids to pregnant animals ...

Effects on ability to drive and use machines

Not relevant.

Undesirable effects

Local adverse reactions include post-injection flare, and a painless destruction of the joint reminiscent of Charcots arthropathy especially with repeated intra-articular injection. The incidence of predictable ...

Overdose

It is difficult to define an excessive dose of a corticosteroid as the therapeutic dose will vary according to the indication and patient requirements. Massive IV corticosteroid doses given as a pulse ...

Pharmacodynamic properties

Pharmacotherapeutic group: Corticosteroids for systemic use, Glucocorticoids ATC code: H02AB02 Dexamethasone is a synthetic adrenocorticoid with approximately a 7 times higher anti-inflammatory potency ...

Pharmacokinetic properties

Absorption After administration of Dexamethasone solution for injection, dexamethasone sodium phosphate is rapidly hydrolysed to dexamethasone. After an IV dose of 20 mg dexamethasone plasma levels peak ...

Preclinical safety data

In animal studies, cleft palate was observed in rats, mice, hamsters, rabbits, dogs and primates; not in horses and sheep. In some cases these divergences were combined with defects of the central nervous ...

List of excipients

Glycerol (E422) Disodium edetate Water for injections Sodium hydroxide (E524) or Phosphoric acid (E338)

Incompatibilities

None known.

Shelf life

Shelf life As packaged for sale: 2 years. The product should be used immediately after first opening. Following dilution with infusion fluids (see section 6.6): Chemical and physical in-use stability of ...

Special precautions for storage

As packaged for sale: Store in a refrigerator (2°C-8°C). Do not freeze. Store in the original package. Following dilution with infusion fluids: See section 6.3.

Nature and contents of container

2 ml colourless glass vial containing 1 ml of solution. Available in cartons of 1 or 10 vials. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

Dexamethasone solution for injection may be diluted with the following solutions for injection or infusion: Sodium Chloride 0.9% infusion Glucose 5% Infusion Compound Sodium Lactate Infusion Hartmanns ...

Marketing authorization holder

Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland

Marketing authorization number(s)

PL 39699/0060

Date of first authorization / renewal of the authorization

Date of first authorisation: 31 March 1989 Date of latest renewal: 18 June 2010

Date of revision of the text

28/11/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.